High Court’s ‘Skinny Label’ Ruling Boosts Patent Case Defenses

The US Supreme Court’s recent ruling protecting generic-drug “skinny labels” has the potential to give technology, medical-device, and other companies a new weapon against allegations of encouraging patent infringement.

The justices last week unanimously ruled that Amarin Pharma Inc. failed to plausibly allege that Hikma Pharmaceuticals Plc induced doctors to prescribe its generic version of Amarin’s heart-health drug Vascepa for a still-patented treatment method.

The decision turned on what conduct amounts to active encouragement of infringement, rejecting arguments based on ambiguous statements and speculation about how others might interpret them.

The ruling’s potential reach beyond drugmakers stems from its treatment of induced infringement—a theory used across patent litigation when companies are accused of causing third parties to violate patent rights.

Legal observers say the decision could influence fights over the evidence needed to prove such claims, with lower courts left to determine how broadly its reasoning applies.

Shashank Upadhye, a managing partner at Upadhye Tang LLP who represents both branded- and generic-drug companies in patent and US Food and Drug Administration litigation, said “the opinion is really about the outer boundaries of inducement liability.”

The high court “essentially said that patent law does not punish a company because someone else might infer an infringing use from an otherwise lawful statement,” Upadhye said.

But Erick Palmer, a lawyer at Honigman LLP who typically represents branded drug companies, said the nature of the pharmaceutical industry is likely to cabin the decision’s reach beyond the context of skinny-label drug approvals.

“In inducement cases involving other technologies and industries, you don’t typically have a regulatory scheme at play like the one in the pharmaceutical industry,” he said. Product instructions, marketing materials, and customer communications “will remain viable sources of evidence sufficient to plead inducement claims” in those cases, Palmer said.

‘Nature of Inducement’

Amarin sued Hikma in 2020 in Delaware district court shortly after the latter began marketing a Vascepa copy with a skinny label approved by the FDA. The label described using the drug—a fish oil derivative—to treat severe hypertriglyceridemia and carved out mentions of using the drug to treat cardiovascular risk.

The US Court of Appeals for the Federal Circuit reversed the district judge’s dismissal, but the justices said the Federal Circuit applied the wrong test for evaluating induced infringement.

Courts historically have wrestled with what kinds of statements or actions are enough to show a company encouraged infringement, particularly when products have both infringing and noninfringing uses.

The Supreme Court clarified “the nature of inducement generally,” said Charles Duan, a patent law professor at American University—specifically, that such liability requires “clear, affirmative acts as opposed to vague or speculative theories.”

It’s also now clear, he said, that statements about equivalence or actions taken to comply with legal requirements alone aren’t enough to trigger liability.

Generic-drug makers often must describe their products as equivalent to branded drugs, but the Supreme Court said those types of statements don’t necessarily encourage doctors to use the products in infringing ways.

The guidance on induced infringement “makes the decision apply to a wide variety of industries,” Duan said. “Statements of equivalence are common in industries like software and consumer goods.”

“All of those industries were at risk under the Federal Circuit decision but now are less likely to be liable,” he said. “In particular, computer device companies” often faced accusations of encouraging customers to infringe software-related patents, but “such suits would be much harder to bring now,” Duan said.

Summary Judgment

Randy McCarthy, head of the IP Law Group at Hall Estill, said the decision is likely to have the most immediate impacts on “high-stakes ongoing” litigation involving medical devices, software, and consumer electronics.

They include disputes over dual-use surgical systems, software instructions or user interfaces that allegedly encourage infringing configurations, and configurable wireless or health-tracking features, he said.

Patent owners in such cases often rely on allegations tied to product capabilities, generalized training materials, and companies’ knowledge of how customers use their products, he said.

The Supreme Court has now made it harder to rely on those theories without evidence of affirmative encouragement, McCarthy said.

Like skinny label cases, this type of litigation often involves products with many potential uses, where only one accused use allegedly infringes, said Joe Micallef, an IP partner at Axinn, Veltrop & Harkrider LLP who has litigated technology patent cases for more than three decades.

“We may see some additional motions to dismiss in cases where they would not otherwise have been filed,” he said, “but I think the broader impact will be in arguments about what is required to prove induced infringement at trial.”

The ruling means “it’s not enough to prove third parties could interpret a defendant’s statements as encouraging infringement,” he said. “At trial you have to prove that the defendant actively encouraged infringement. I think we will see a lot of summary judgment motions based on this distinction.”

Unanswered Questions

Paul Schoenhard, a trial and appellate lawyer at McGuireWoods who focuses on complex intellectual property disputes, said the Supreme Court did leave some unanswered questions, including when conduct crosses the line.

The decision left room for liability based on “implicit encouragement,” which Schoenhard said will be “fertile ground for further development.”

Still, “the ultimate scope of the decision remains to be seen because the FDA and regulatory context was a significant component of the court’s analysis,” said Taylor Weilnau, a patent attorney who specializes in life sciences at McDonnell Beohnen Hulbert & Berghoff, which represents both branded- and generic- drug companies.

The decision may give defendants new arguments for challenging inducement allegations early, but future cases will determine “how broadly courts apply its reasoning outside the regulatory framework that gave rise to the dispute,” she said.

The case is Hikma Pharms. USA Inc. v. Amarin Pharma, Inc., 2026 BL 207741, U.S., 24-889, 6/4/26.